Hub : Traits :

Hypothyroidism/myxoedema (self-reported)

550 significantly associated models · 151 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	2288852	2761863	2	1	1.8e-09	1.4e-07	1.4e-01	92	MMEL1
2	1	18940380	20503710	2	1	2.2e-09	3.5e-10	7.0e-07	38	CAPZB
3	1	23431777	24861704	2	1	1.9e-07	6.0e-07	2.2e-01	94	HMGCL
4	1	38077067	38661361	1	1	2.2e-07	1.2e-07	3.3e-07	7	INPP5B
5	1	107418424	109188382	1	1	2.6e-36	1.6e-36	1.0e+00	100	VAV3
6	1	113236087	115222434	10	10	1.2e-56	3.5e-124	NaN	NaN	AP4B1 BCL2L15 DCLRE1B HIPK1 OLFML3 PHTF1 RSBN1
7	1	156078249	157482371	1	1	1.5e-07	4.9e-08	1.3e-01	92	SH2D2A
8	2	190521054	192712723	6	3	9.3e-11	7.7e-29	4.0e-17	43	NAB1 STAT4 TMEM194B
9	3	11350553	12928762	2	1	1.4e-08	7.7e-08	4.5e-01	98	TIMP4
10	3	36339386	38174470	4	1	4.4e-09	1.2e-08	5.7e-02	89	LRRFIP2
11	4	122961964	124352460	1	1	2.7e-07	3.4e-08	3.3e-02	85	BBS12
12	4	148303195	150060844	1	1	6.1e-21	2.5e-21	1.0e+00	100	NR3C2
13	5	71557313	73083183	1	1	2.1e-07	9.8e-07	8.9e-05	36	FCHO2
14	5	75812681	77412011	1	1	1.1e-07	2.1e-09	5.2e-03	78	PDE8B
15	5	101392473	103061825	1	1	1.7e-09	1.2e-09	9.8e-02	93	PAM
16	6	25296606	26689223	1	1	6.5e-09	9.6e-12	1.2e-06	49	U91328.19
17	6	35216296	35942313	2	1	8.1e-10	1.4e-08	1.5e-01	94	TULP1
18	6	89941356	91704536	1	1	7.0e-27	4.0e-29	6.5e-14	55	BACH2
19	6	134905567	136516257	3	1	1.3e-10	1.7e-09	1.0e-02	82	C6orf217
20	6	166651581	167841508	5	1	6.8e-25	3.9e-24	1.0e+00	100	RNASET2
21	7	99591418	100979310	2	1	5.7e-10	1.5e-09	1.0e+00	100	GIGYF1
22	8	8092025	12973575	22	1	4.1e-16	1.6e-18	1.0e+00	100	SGK223
23	8	60736025	62220903	1	1	2.6e-08	3.9e-08	1.0e+00	100	RAB2A
24	8	133089975	134846363	2	1	5.6e-11	2.5e-12	1.1e-04	70	TG
25	9	99581811	101652673	7	10	2.6e-50	2.1e-71	NaN	NaN	C9orf156 FOXE1 NCBP1 TMOD1
26	10	5027660	6677767	2	2	1.8e-15	2.9e-15	6.2e-02	94	FAM208B FBXO18
27	10	16986810	18453209	1	1	8.4e-08	6.0e-07	1.0e+00	100	STAM
28	10	63253359	64724096	1	1	4.9e-10	5.8e-19	7.7e-18	6	RTKN2
29	11	35028935	35689490	1	1	3.3e-15	2.5e-14	2.4e-03	84	SLC1A2
30	11	60846825	62326265	3	1	8.7e-08	1.4e-07	4.3e-01	98	FADS2
31	12	55601472	57125879	6	1	1.4e-13	2.0e-11	8.0e-02	93	SUOX
32	12	109641978	113517494	21	8	8.5e-48	1.1e-81	NaN	NaN	ADAM1A ALDH2 HECTD4 RP3-462E2.3 VPS29
33	15	38088200	39556796	1	1	7.4e-11	4.4e-12	1.5e-02	88	RASGRP1
34	16	49650937	51097687	1	1	1.1e-07	3.8e-07	3.0e-01	96	BRD7
35	16	66773300	68365955	3	1	7.9e-08	4.3e-08	1.9e-01	94	ATP6V0D1
36	17	6190353	7949434	2	1	2.1e-07	1.7e-11	2.3e-06	51	RP11-589P10.7
37	17	39589083	41265776	3	1	3.5e-12	3.1e-12	1.0e+00	100	HSPB9
38	17	44788310	46602432	4	1	1.8e-13	5.4e-13	4.3e-03	84	NPEPPS
39	18	66371289	68204223	2	1	6.3e-09	1.8e-09	1.0e+00	100	DOK6
40	19	4118871	5529588	2	2	2.5e-09	7.2e-15	3.3e-05	72	FEM1A TICAM1
41	19	17672385	19190906	3	1	2.8e-08	7.6e-10	2.8e-05	54	JUND
42	19	49279612	50909389	3	2	1.3e-10	1.7e-10	1.0e+00	100	CPT1C RPS11
43	22	30233446	30820707	1	1	8.9e-09	9.8e-11	1.8e-03	77	HORMAD2
44	22	36867133	38292974	3	3	1.8e-17	8.8e-22	2.2e-01	98	C1QTNF6 SSTR3
45	22	39064209	40479448	1	1	2.4e-07	2.8e-07	1.0e+00	100	SYNGR1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Hypothyroidism (self reported)	35.01	63	60	133.3	1.00	1.4e-77	ADAM1A ALDH2 AP4B1 ATP6V0D1 BACH2 BBS12 BCL2L15 BRD7 C1QTNF6 C6orf217 C9orf156 CAPZB CPT1C DCLRE1B DOK6 FADS2 FAM208B FBXO18 FCHO2 FEM1A FOXE1 GIGYF1 HECTD4 HIPK1 HMGCL HORMAD2 HSPB9 INPP5B JUND LRRFIP2 MMEL1 NAB1 NCBP1 NPEPPS NR3C2 OLFML3 PAM PDE8B PHTF1 RAB2A RASGRP1 RNASET2 RP11-589P10.7 RP3-462E2.3 RPS11 RSBN1 RTKN2 SGK223 SH2D2A SLC1A2 SSTR3 STAM STAT4 SUOX SYNGR1 TG TICAM1 TIMP4 TMEM194B TMOD1 TULP1 VAV3 VPS29
Medication: Levothyroxine sodium	26.50	61	38	84.4	1.00	2.8e-78	ADAM1A ALDH2 AP4B1 ATP6V0D1 BACH2 BCL2L15 BRD7 C1QTNF6 C6orf217 C9orf156 CAPZB CPT1C DCLRE1B DOK6 FADS2 FAM208B FBXO18 FCHO2 FEM1A FOXE1 GIGYF1 HECTD4 HIPK1 HORMAD2 HSPB9 INPP5B JUND LRRFIP2 MMEL1 NAB1 NCBP1 NPEPPS NR3C2 OLFML3 PAM PDE8B PHTF1 RAB2A RASGRP1 RNASET2 RP11-589P10.7 RP3-462E2.3 RSBN1 RTKN2 SGK223 SH2D2A SLC1A2 SSTR3 STAM STAT4 SUOX SYNGR1 TG TICAM1 TIMP4 TMEM194B TMOD1 TULP1 U91328.19 VAV3 VPS29
Rheumatoid Arthritis	13.29	15	7	15.6	0.96	2.3e-10	AP4B1 BCL2L15 DCLRE1B FAM208B HECTD4 HIPK1 INPP5B MMEL1 NAB1 OLFML3 PAM PHTF1 RASGRP1 RSBN1 SYNGR1
Blood Eosinophil Count	10.79	24	19	42.2	0.69	6.4e-05	ADAM1A ALDH2 BACH2 BBS12 C1QTNF6 DOK6 FADS2 FAM208B FBXO18 FCHO2 GIGYF1 HECTD4 HMGCL JUND NAB1 NPEPPS RASGRP1 RP3-462E2.3 SLC1A2 SSTR3 STAT4 SUOX TIMP4 VPS29
Blood Platelet Count	5.43	17	11	24.4	0.35	1.0e-01	ADAM1A C1QTNF6 C9orf156 CAPZB DOK6 FADS2 FCHO2 FOXE1 HECTD4 NAB1 PAM RP3-462E2.3 SH2D2A SYNGR1 TIMP4 TMOD1 VPS29
Blood White Count	5.23	22	15	33.3	0.33	8.7e-02	ADAM1A ALDH2 AP4B1 ATP6V0D1 BACH2 BCL2L15 C6orf217 DCLRE1B DOK6 FADS2 HECTD4 HORMAD2 HSPB9 INPP5B PAM PDE8B PHTF1 RAB2A RP11-589P10.7 RP3-462E2.3 TIMP4 VPS29
Taking other prescription medications	4.92	10	5	11.1	0.97	1.0e-07	ADAM1A BCL2L15 C6orf217 DCLRE1B FAM208B HECTD4 HIPK1 HSPB9 PHTF1 RNASET2
Lupus	4.14	6	2	4.4	0.70	5.1e-02	DCLRE1B HECTD4 NAB1 RTKN2 SGK223 TMEM194B
Long-standing illness, disability or infirmity	3.24	5	1	2.2	0.97	1.0e-03	BCL2L15 DCLRE1B FAM208B PHTF1 RNASET2
Primary Biliary Cirrhosis	3.09	5	1	2.2	0.66	1.6e-01	DOK6 HECTD4 MMEL1 NAB1 SYNGR1
Diastolic blood pressure, automated reading	3.05	9	7	15.6	0.63	2.8e-02	ADAM1A ALDH2 GIGYF1 HECTD4 INPP5B RP3-462E2.3 SGK223 TMEM194B VPS29
Crohns Disease (2017)	2.94	9	3	6.7	-0.45	2.0e-01	BCL2L15 CPT1C DCLRE1B FADS2 GIGYF1 HIPK1 HORMAD2 RNASET2 SYNGR1
Number of treatments/medications taken	2.78	7	2	4.4	0.96	2.8e-05	ADAM1A BCL2L15 DCLRE1B FADS2 FAM208B HECTD4 RNASET2
Number of self-reported non-cancer illnesses	2.75	3	1	2.2	1.00	4.0e-03	FAM208B HECTD4 RNASET2
Other serious medical condition/disability diagnosed by doctor	2.71	1	0	0.0	0.00	1.0e+00	DCLRE1B
Hayfever, allergic rhinitis or eczema	2.66	8	4	8.9	-0.36	3.8e-01	ADAM1A BACH2 BBS12 C6orf217 FBXO18 HECTD4 SUOX U91328.19
Allergy or Eczema	2.63	7	7	15.6	-0.28	5.1e-01	ADAM1A BACH2 BBS12 C6orf217 FBXO18 HECTD4 SUOX
Blood Red Count	2.62	19	14	31.1	0.34	1.3e-01	ADAM1A ALDH2 ATP6V0D1 BACH2 C9orf156 CPT1C FADS2 GIGYF1 HECTD4 HMGCL NAB1 NPEPPS PAM RP3-462E2.3 RPS11 SUOX TG TMEM194B VPS29
LDL Cholesterol	2.58	3	2	4.4	0.81	9.7e-02	ALDH2 FADS2 HECTD4
Birth weight of first child	2.53	7	2	4.4	-0.53	1.4e-01	ADAM1A ALDH2 FCHO2 HECTD4 RAB2A RP3-462E2.3 SUOX
Birth weight	2.44	7	2	4.4	-0.78	2.3e-02	ADAM1A ALDH2 DCLRE1B HECTD4 HORMAD2 SUOX VPS29
Pulse rate, automated reading	2.40	6	3	6.7	-0.56	2.5e-01	FADS2 GIGYF1 JUND NAB1 TMEM194B VPS29
Respiratory disease	2.38	7	4	8.9	-0.82	2.4e-02	BACH2 BBS12 C6orf217 FADS2 FAM208B FBXO18 SUOX
Asthma (self-reported)	2.34	7	3	6.7	0.13	7.9e-01	BACH2 BBS12 C6orf217 FADS2 FBXO18 INPP5B SUOX
Coronary Artery Disease (CAD)	2.31	2	0	0.0	0.00	1.0e+00	HECTD4 VPS29
Crohns Disease (2012)	2.29	5	1	2.2	-0.45	4.5e-01	DCLRE1B FADS2 HIPK1 HORMAD2 RNASET2
Allergy	2.27	8	4	8.9	0.33	4.3e-01	ADAM1A BACH2 BBS12 C6orf217 FADS2 FBXO18 SUOX U91328.19
Irritable Bowel Disease (IBD)	2.26	7	2	4.4	0.70	8.1e-02	BBS12 BRD7 CPT1C HECTD4 HORMAD2 RNASET2 SYNGR1
Asthma	2.24	6	3	6.7	0.12	8.2e-01	BACH2 BBS12 C6orf217 FADS2 INPP5B SUOX
Medication: Atenolol	2.22	1	1	2.2	0.00	1.0e+00	HECTD4
Reaction Time	2.20	3	2	4.4	0.96	9.6e-03	ALDH2 HECTD4 RP3-462E2.3
Systolic Blood Pressure	2.19	8	7	15.6	0.68	3.0e-02	ADAM1A ALDH2 HECTD4 HMGCL NAB1 RP3-462E2.3 TMEM194B VPS29
Mouth/teeth dental problems: Mouth ulcers	2.18	3	1	2.2	0.00	1.0e+00	BRD7 FEM1A PAM
Hayfever/allergic rhinitis (self-reported)	2.15	3	0	0.0	0.00	1.0e+00	C6orf217 SUOX U91328.19
Neuroticism score	1.98	4	1	2.2	0.65	3.5e-01	HORMAD2 SGK223 TIMP4 U91328.19
Mean time to correctly identify matches	1.97	3	2	4.4	0.97	7.4e-03	ALDH2 HECTD4 RP3-462E2.3
Pulse rate	1.87	2	2	4.4	0.00	1.0e+00	FADS2 GIGYF1
High blood pressure	1.86	6	3	6.7	0.17	6.8e-01	ADAM1A ALDH2 HECTD4 RTKN2 SGK223 SUOX
Vascular/heart problems diagnosed by doctor	1.83	7	4	8.9	-0.40	2.9e-01	ADAM1A ALDH2 HECTD4 RTKN2 SGK223 SUOX VPS29
Cardiovascular Disease	1.79	5	3	6.7	0.77	4.1e-02	ADAM1A ALDH2 HECTD4 SUOX VPS29
Past tobacco smoking	1.79	5	0	0.0	0.01	9.8e-01	ADAM1A ALDH2 HECTD4 PHTF1 SUOX
Headache pain in last month	1.79	1	0	0.0	0.00	1.0e+00	ALDH2
Waist Hip Ratio (WHR)	1.75	8	5	11.1	0.24	5.7e-01	ADAM1A ATP6V0D1 BACH2 BBS12 JUND PAM SYNGR1 TIMP4
Smoking status: Previous	1.75	3	0	0.0	0.79	1.1e-01	ALDH2 HECTD4 SUOX
HDL Cholesterol	1.72	1	1	2.2	0.00	1.0e+00	FADS2
Fed-up feelings	1.72	4	1	2.2	-0.61	1.9e-01	ALDH2 HECTD4 HORMAD2 SGK223
Medication: Blood pressure	1.71	3	2	4.4	0.52	3.6e-01	ALDH2 HECTD4 SGK223
Worry too long after embarrassment	1.69	2	1	2.2	0.00	1.0e+00	C6orf217 SGK223
Hypertension (Self-reported)	1.68	6	3	6.7	0.14	7.5e-01	ADAM1A ALDH2 HECTD4 RTKN2 SGK223 SUOX
Triglycerides	1.67	1	1	2.2	0.00	1.0e+00	FADS2
Number of live births	1.67	2	0	0.0	0.00	1.0e+00	FADS2 HORMAD2
Breast Cancer	1.66	4	2	4.4	-0.97	2.7e-04	AP4B1 BCL2L15 DCLRE1B PHTF1
Medication: Blood pressure	1.66	3	1	2.2	0.91	8.8e-02	ADAM1A ALDH2 HECTD4
Worrier / anxious feelings	1.65	2	1	2.2	0.00	1.0e+00	PAM SGK223
Ulcerative Colitis (UC)	1.64	2	0	0.0	0.00	1.0e+00	BBS12 SYNGR1
Pulse wave Arterial Stiffness index	1.64	1	1	2.2	0.00	1.0e+00	ADAM1A
Pulse wave peak to peak time	1.62	1	1	2.2	0.00	1.0e+00	ADAM1A
Systolic blood pressure, automated reading	1.61	5	3	6.7	0.18	7.0e-01	ALDH2 HECTD4 NAB1 SGK223 TMEM194B
Father's age at death	1.61	1	0	0.0	0.00	1.0e+00	HECTD4
Seen a psychiatrist for nerves, anxiety, tension or depression	1.60	2	0	0.0	0.00	1.0e+00	TIMP4 U91328.19
Reason for reducing amount of alcohol drunk: Health precaution	1.59	1	0	0.0	0.00	1.0e+00	SUOX
Suffer from 'nerves'	1.59	1	0	0.0	0.00	1.0e+00	SGK223
Ever smoked	1.58	1	0	0.0	0.00	1.0e+00	PHTF1
Medication: Ibuprofen (e.g. Nurofen)	1.57	1	0	0.0	0.00	1.0e+00	HECTD4
Heel bone mineral density (BMD) T-score, automated (right)	1.56	4	1	2.2	-0.50	5.0e-01	CAPZB FADS2 SGK223 U91328.19
Miserableness	1.56	2	1	2.2	0.00	1.0e+00	HORMAD2 SGK223
Irritability	1.56	3	1	2.2	0.00	1.0e+00	FADS2 FCHO2 SGK223
Arm predicted mass (left)	1.56	10	7	15.6	-0.77	3.3e-03	ADAM1A ALDH2 HECTD4 HORMAD2 RP3-462E2.3 SGK223 SUOX SYNGR1 U91328.19 VPS29
Arm fat-free mass (left)	1.55	10	8	17.8	-0.77	5.7e-03	ADAM1A ALDH2 HECTD4 HORMAD2 RP3-462E2.3 SGK223 SUOX SYNGR1 U91328.19 VPS29
Neuroticism (Nagel 2018)	1.54	3	0	0.0	0.00	1.0e+00	HORMAD2 RNASET2 TIMP4
Comparative height size at age 10	1.54	10	4	8.9	-0.85	3.0e-05	ALDH2 ATP6V0D1 C9orf156 CAPZB HECTD4 HORMAD2 INPP5B NR3C2 PDE8B RPS11
Fasting Glucose	1.53	1	0	0.0	0.00	1.0e+00	FADS2
Ulcerative Colitis	1.53	1	0	0.0	0.00	1.0e+00	BRD7
Arm predicted mass (right)	1.52	10	7	15.6	-0.76	7.2e-03	ADAM1A ALDH2 HECTD4 HORMAD2 RP3-462E2.3 SGK223 SUOX SYNGR1 U91328.19 VPS29
Medication for cholesterol	1.51	1	0	0.0	0.00	1.0e+00	HECTD4
Sensitivity / hurt feelings	1.50	1	1	2.2	0.00	1.0e+00	SGK223
Nervous feelings	1.50	2	2	4.4	0.00	1.0e+00	SGK223 U91328.19
Impedance of arm (right)	1.50	10	5	11.1	0.54	1.1e-01	ADAM1A BBS12 C6orf217 HECTD4 JUND NR3C2 RTKN2 SGK223 SUOX VPS29
Myopia	1.50	1	0	0.0	0.00	1.0e+00	FADS2
Arm fat-free mass (right)	1.49	10	6	13.3	-0.76	6.7e-03	ADAM1A ALDH2 HECTD4 HORMAD2 RP3-462E2.3 SGK223 SUOX SYNGR1 U91328.19 VPS29
Heel bone mineral density (BMD) T-score, automated (left)	1.48	3	1	2.2	0.00	1.0e+00	FADS2 SGK223 U91328.19
High blood pressure (siblings)	1.48	1	0	0.0	0.00	1.0e+00	HECTD4
Mood swings	1.48	2	1	2.2	0.00	1.0e+00	HORMAD2 SGK223
Chronotype (morning person)	1.47	4	0	0.0	0.44	4.6e-01	ALDH2 HECTD4 HORMAD2 TIMP4
Hip circumference	1.47	7	5	11.1	-0.66	5.1e-02	ALDH2 HECTD4 RP3-462E2.3 SGK223 SYNGR1 U91328.19 VPS29
Tense / 'highly strung'	1.47	2	1	2.2	0.00	1.0e+00	SGK223 TIMP4
Neuroticism (2016)	1.46	1	1	2.2	0.00	1.0e+00	SGK223
Lung FVC	1.46	12	3	6.7	0.06	8.5e-01	AP4B1 C6orf217 HECTD4 HORMAD2 HSPB9 JUND PAM PDE8B RP3-462E2.3 SUOX TMEM194B TULP1
Leg fat percentage (right)	1.44	3	2	4.4	0.00	1.0e+00	JUND SGK223 U91328.19
Ever unenthusiastic/disinterested for a whole week	1.43	1	0	0.0	0.00	1.0e+00	TIMP4
Impedance of arm (left)	1.43	8	5	11.1	0.76	1.8e-02	ADAM1A BBS12 HECTD4 JUND RP3-462E2.3 SGK223 SUOX VPS29
Average weekly beer plus cider intake	1.43	1	0	0.0	0.00	1.0e+00	SGK223
Medication: Ventolin 100micrograms inhaler	1.42	2	0	0.0	0.00	1.0e+00	BACH2 STAM
Weight	1.41	10	4	8.9	-0.35	2.9e-01	ALDH2 HECTD4 HORMAD2 LRRFIP2 SGK223 SUOX SYNGR1 TULP1 U91328.19 VPS29
Leg fat mass (right)	1.41	6	3	6.7	-0.66	1.0e-01	ALDH2 HECTD4 JUND SGK223 U91328.19 VPS29
Leg fat mass (left)	1.41	6	3	6.7	-0.43	3.4e-01	HECTD4 JUND LRRFIP2 SGK223 U91328.19 VPS29
Depressed Affect (Nagel 2018)	1.40	1	0	0.0	0.00	1.0e+00	HORMAD2
Worry (Nagel 2018)	1.40	4	0	0.0	0.60	4.0e-01	HORMAD2 PAM TIMP4 U91328.19
Frequency of tiredness / lethargy in last 2 weeks	1.40	1	0	0.0	0.00	1.0e+00	ALDH2
Guilty feelings	1.40	1	0	0.0	0.00	1.0e+00	SGK223
Basal metabolic rate	1.40	11	6	13.3	-0.70	1.2e-02	ADAM1A ALDH2 HECTD4 HORMAD2 INPP5B RP3-462E2.3 SGK223 SUOX SYNGR1 U91328.19 VPS29
Leg fat percentage (left)	1.40	3	2	4.4	0.00	1.0e+00	JUND SGK223 U91328.19
Type 2 Diabetes (T2D) (2018)	1.39	1	0	0.0	0.00	1.0e+00	ADAM1A
Trunk predicted mass	1.39	11	5	11.1	-0.61	2.7e-02	ADAM1A ALDH2 HECTD4 HORMAD2 INPP5B JUND RP3-462E2.3 SUOX SYNGR1 U91328.19 VPS29
Trunk fat-free mass	1.38	11	5	11.1	-0.61	2.8e-02	ADAM1A ALDH2 HECTD4 HORMAD2 INPP5B JUND RP3-462E2.3 SUOX SYNGR1 U91328.19 VPS29
Loneliness, isolation	1.38	1	0	0.0	0.00	1.0e+00	RNASET2
Average weekly champagne plus white wine intake	1.38	2	0	0.0	0.00	1.0e+00	FADS2 SUOX
Whole body fat-free mass	1.37	11	4	8.9	-0.71	1.0e-02	ADAM1A ALDH2 HECTD4 HORMAD2 INPP5B RP3-462E2.3 SGK223 SUOX SYNGR1 U91328.19 VPS29
Whole body water mass	1.37	11	4	8.9	-0.71	9.2e-03	ADAM1A ALDH2 HECTD4 HORMAD2 INPP5B RP3-462E2.3 SGK223 SUOX SYNGR1 U91328.19 VPS29
Overall health rating	1.36	3	0	0.0	0.00	1.0e+00	BCL2L15 SGK223 SUOX
Medication: Ramipril	1.34	1	0	0.0	0.00	1.0e+00	ADAM1A
Neuroticism	1.33	2	0	0.0	0.00	1.0e+00	HORMAD2 TIMP4
Bipolar Disorder or Schizophrenia	1.32	2	0	0.0	0.00	1.0e+00	LRRFIP2 SGK223
Illnesses of siblings	1.31	2	0	0.0	0.00	1.0e+00	ADAM1A HECTD4
Qualifications: NVQ or HND or HNC or equivalent	1.31	1	0	0.0	0.00	1.0e+00	ALDH2
Impedance of whole body	1.31	9	4	8.9	0.61	8.1e-02	ADAM1A ATP6V0D1 BBS12 HECTD4 JUND RTKN2 SGK223 SUOX VPS29
Lung FEV1/FVC ratio	1.30	8	4	8.9	-0.28	5.0e-01	ATP6V0D1 C9orf156 JUND NCBP1 PHTF1 RPS11 SLC1A2 SUOX
Trunk fat mass	1.30	5	3	6.7	0.66	2.2e-01	JUND LRRFIP2 SYNGR1 TULP1 U91328.19
Whole body fat mass	1.30	7	2	4.4	-0.03	9.4e-01	HECTD4 JUND LRRFIP2 SGK223 SYNGR1 TULP1 U91328.19
High cholesterol (Self-reported)	1.30	1	0	0.0	0.00	1.0e+00	FADS2
Leg fat-free mass (right)	1.29	8	5	11.1	-0.64	6.5e-02	HECTD4 HORMAD2 INPP5B SGK223 SUOX SYNGR1 U91328.19 VPS29
Leg predicted mass (right)	1.28	8	5	11.1	-0.64	6.5e-02	HECTD4 HORMAD2 INPP5B SGK223 SUOX SYNGR1 U91328.19 VPS29
Schizophrenia (2018)	1.27	1	0	0.0	0.00	1.0e+00	U91328.19
Friendships satisfaction	1.27	1	0	0.0	0.00	1.0e+00	VPS29
Medication: Bendroflumethiazide	1.27	1	0	0.0	0.00	1.0e+00	SGK223
Vitamin and mineral supplements	1.26	1	0	0.0	0.00	1.0e+00	U91328.19
Mouth/teeth dental problems: Dentures	1.26	2	1	2.2	0.00	1.0e+00	SGK223 U91328.19
Leg fat-free mass (left)	1.25	9	5	11.1	-0.64	4.6e-02	ALDH2 HECTD4 HORMAD2 INPP5B SGK223 SUOX SYNGR1 U91328.19 VPS29
Trunk fat percentage	1.25	4	3	6.7	0.56	4.4e-01	JUND LRRFIP2 TULP1 U91328.19
Leg predicted mass (left)	1.25	8	4	8.9	-0.62	7.3e-02	HECTD4 HORMAD2 INPP5B SGK223 SUOX SYNGR1 U91328.19 VPS29
Body fat percentage	1.25	4	2	4.4	0.60	4.0e-01	JUND LRRFIP2 TULP1 U91328.19
Neck or shoulder pain in last month	1.25	1	0	0.0	0.00	1.0e+00	SUOX
Age when periods started (menarche)	1.23	2	0	0.0	0.00	1.0e+00	DCLRE1B SUOX
Gout (self-reported)	1.23	1	0	0.0	0.00	1.0e+00	HECTD4
Verbal and Numeric Reasoning (VNR)	1.22	4	0	0.0	0.88	1.2e-01	C6orf217 FADS2 PAM SUOX
Mineral and other dietary supplements	1.22	1	0	0.0	0.00	1.0e+00	SGK223
Pain experienced in last month	1.20	3	0	0.0	0.00	1.0e+00	ALDH2 HECTD4 SUOX
Impedance of leg (right)	1.19	6	3	6.7	0.31	5.5e-01	ATP6V0D1 FCHO2 JUND PAM SGK223 SUOX
Qualifications: A levels/AS levels or equivalent	1.19	1	0	0.0	0.00	1.0e+00	SUOX
Arm fat mass (right)	1.19	7	3	6.7	-0.30	5.2e-01	HECTD4 JUND LRRFIP2 SGK223 SUOX SYNGR1 U91328.19
Smoking Status	1.18	3	1	2.2	0.00	1.0e+00	ADAM1A PHTF1 SUOX
Body mass index (BMI)	1.17	4	2	4.4	-0.57	4.3e-01	HECTD4 SGK223 SUOX U91328.19
Standing height	1.17	15	10	22.2	-0.27	2.5e-01	ALDH2 ATP6V0D1 C9orf156 CAPZB FADS2 HECTD4 HORMAD2 HSPB9 INPP5B NAB1 NPEPPS RPS11 SGK223 SYNGR1 U91328.19
Bipolar Disorder (2018)	1.16	2	0	0.0	0.00	1.0e+00	FADS2 LRRFIP2
Wheeze or whistling in the chest in last year	1.16	1	0	0.0	0.00	1.0e+00	FADS2
Supplements: Fish oil (including cod liver oil)	1.16	1	0	0.0	0.00	1.0e+00	SGK223
Waist circumference	1.14	4	2	4.4	-0.83	1.7e-01	ALDH2 HECTD4 JUND U91328.19
Qualifications: None of the above	1.14	1	0	0.0	0.00	1.0e+00	SUOX
Qualifications: College or University degree	1.14	3	2	4.4	0.00	1.0e+00	JUND PAM SUOX
Arm fat mass (left)	1.14	6	3	6.7	-0.22	6.7e-01	HECTD4 JUND LRRFIP2 SGK223 SYNGR1 U91328.19
Impedance of leg (left)	1.13	5	3	6.7	0.71	1.8e-01	ATP6V0D1 JUND PAM SGK223 SUOX
Hair/balding pattern: Pattern 4	1.13	2	1	2.2	0.00	1.0e+00	ATP6V0D1 FADS2
HbA1C	1.12	1	0	0.0	0.00	1.0e+00	ADAM1A
Forced expiratory volume in 1-second (FEV1)	1.12	4	1	2.2	-0.44	5.6e-01	C6orf217 HORMAD2 SGK223 SUOX
Medication: Simvastatin	1.11	1	0	0.0	0.00	1.0e+00	FADS2
Schizophrenia (2014)	1.10	2	0	0.0	0.00	1.0e+00	GIGYF1 SGK223
Height	1.10	23	17	37.8	-0.45	1.5e-02	ADAM1A ALDH2 ATP6V0D1 C9orf156 CAPZB CPT1C FADS2 HECTD4 HORMAD2 HSPB9 INPP5B LRRFIP2 NAB1 NCBP1 NPEPPS NR3C2 PAM RP3-462E2.3 RPS11 SLC1A2 SYNGR1 TMOD1 TULP1
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.10	1	1	2.2	0.00	1.0e+00	U91328.19
Forced vital capacity (FVC)	1.09	5	2	4.4	-0.70	1.8e-01	ATP6V0D1 C6orf217 HORMAD2 INPP5B RPS11
Hearing difficulty/problems with background noise	1.07	1	0	0.0	0.00	1.0e+00	U91328.19
Supplements: Vitamin C	1.07	1	0	0.0	0.00	1.0e+00	U91328.19
Medication: Gliclazide	1.05	1	0	0.0	0.00	1.0e+00	LRRFIP2
Peak expiratory flow (PEF)	1.04	2	1	2.2	0.00	1.0e+00	SGK223 TMEM194B
Arm fat percentage (right)	1.00	4	2	4.4	-0.12	8.8e-01	JUND LRRFIP2 SGK223 U91328.19
Intelligence (Savage-Jansen 2018)	0.99	3	0	0.0	0.00	1.0e+00	FADS2 PAM SUOX
Fluid intelligence score	0.98	1	0	0.0	0.00	1.0e+00	FADS2
Arm fat percentage (left)	0.98	4	3	6.7	-0.11	8.9e-01	JUND LRRFIP2 SGK223 U91328.19
Comparative body size at age 10	0.97	3	1	2.2	0.00	1.0e+00	HORMAD2 SGK223 U91328.19
Alcohol intake frequency.	0.97	2	0	0.0	0.00	1.0e+00	NPEPPS SUOX
Forced expiratory volume in 1-second (FEV1), Best measure	0.96	4	0	0.0	-0.44	5.6e-01	C6orf217 HORMAD2 SGK223 SUOX
Heel T-Score	0.91	8	5	11.1	0.01	9.8e-01	ATP6V0D1 BACH2 CAPZB DCLRE1B FADS2 FCHO2 INPP5B NAB1
Forced vital capacity (FVC), Best measure	0.91	3	1	2.2	0.00	1.0e+00	C6orf217 HORMAD2 INPP5B
Sitting height	0.88	6	4	8.9	0.04	9.3e-01	C9orf156 CAPZB FADS2 HORMAD2 INPP5B U91328.19
Relative age voice broke	0.87	1	0	0.0	0.00	1.0e+00	ADAM1A
BMI	0.73	4	1	2.2	-0.99	1.5e-03	HECTD4 JUND SUOX VPS29
Hair Pigment	0.45	8	7	15.6	0.10	7.4e-01	ALDH2 C9orf156 FADS2 GIGYF1 HECTD4 RP3-462E2.3 SUOX SYNGR1
Tanning	0.28	5	0	0.0	0.62	1.9e-01	ALDH2 HECTD4 JUND RP3-462E2.3 SYNGR1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Putamen basal ganglia	2	0.32	2.3
GTEx	Whole Blood	9	0.45	2.3
NTR	Blood	13	0.54	2.3
The Cancer Genome Atlas	Esophageal Carcinoma	4	0.58	2.3
GTEx	Ovary	7	0.77	2.2
GTEx	Adrenal Gland	5	0.34	2.1
GTEx	Brain Cerebellar Hemisphere	8	0.54	2.1
GTEx	Brain Cerebellum	7	0.35	2.1
GTEx	Brain Frontal Cortex BA9	4	0.43	2.1
GTEx	Skin Not Sun Exposed Suprapubic	8	0.33	2.1
GTEx	Small Intestine Terminal Ileum	1	0.22	2.1
GTEx	Stomach	6	0.41	2.1
GTEx	Thyroid	17	0.43	2.1
GTEx	Uterus	2	0.35	2.1
GTEx	Vagina	2	0.31	2.1
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	11	0.83	2.1
GTEx	Artery Coronary	4	0.34	2.0
GTEx	Artery Tibial	13	0.35	2.0
GTEx	Brain Caudate basal ganglia	1	0.11	2.0
GTEx	Brain Cortex	4	0.39	2.0
GTEx	Breast Mammary Tissue	5	0.25	2.0
GTEx	Cells EBV-transformed lymphocytes	4	0.28	2.0
GTEx	Colon Sigmoid	6	0.41	2.0
GTEx	Colon Transverse	9	0.44	2.0
GTEx	Esophagus Gastroesophageal Junction	9	0.62	2.0
GTEx	Lung	10	0.35	2.0
GTEx	Nerve Tibial	18	0.42	2.0
GTEx	Pancreas	4	0.25	2.0
GTEx	Pituitary	6	0.54	2.0
GTEx	Prostate	3	0.36	2.0
GTEx	Skin Sun Exposed Lower leg	12	0.33	2.0
GTEx	Testis	13	0.41	2.0
YFS	Blood	17	0.37	2.0
The Cancer Genome Atlas	Breast Invasive Carcinoma	14	0.32	2.0
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	9	0.33	2.0
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	8	0.48	2.0
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.29	2.0
The Cancer Genome Atlas	Testicular Germ Cell Tumors	5	0.39	2.0
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	2.0
GTEx	Adipose Subcutaneous	9	0.26	1.9
GTEx	Adipose Visceral Omentum	4	0.20	1.9
GTEx	Artery Aorta	8	0.27	1.9
GTEx	Brain Nucleus accumbens basal ganglia	4	0.46	1.9
GTEx	Breast Mammary Tissue (Male)	3	0.25	1.9
GTEx	Breast Mammary Tissue (Female)	5	0.30	1.9
GTEx	Cells Transformed fibroblasts	17	0.40	1.9
GTEx	Esophagus Mucosa	9	0.27	1.9
GTEx	Esophagus Muscularis	10	0.31	1.9
GTEx	Heart Atrial Appendage	4	0.25	1.9
GTEx	Heart Left Ventricle	2	0.13	1.9
GTEx	Liver	1	0.14	1.9
GTEx	Muscle Skeletal	13	0.45	1.9
GTEx	Spleen	4	0.28	1.9
METSIM	Adipose	15	0.33	1.9
ROSMAP	Brain Pre-frontal Cortex	17	0.39	1.9
CommonMind	Brain Pre-frontal Cortex	20	0.37	1.9
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.18	1.9
The Cancer Genome Atlas	Colon Adenocarcinoma	8	0.39	1.9
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.29	1.9
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	6	0.29	1.9
The Cancer Genome Atlas	Brain Lower Grade Glioma	16	0.37	1.9
The Cancer Genome Atlas	Lung Adenocarcinoma	12	0.41	1.9
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	10	0.40	1.9
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.38	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	12	0.26	1.9
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.28	1.9
The Cancer Genome Atlas	Thyroid Carcinoma	17	0.33	1.9
GTEx	Brain Hippocampus	1	0.19	1.8
GTEx	Brain Hypothalamus	1	0.17	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.27	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	10	0.24	1.8
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	4	0.36	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	2	0.37	1.8
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.24	1.8